Protocol Ledger

NCT04609566 · Phase II · COMPLETED

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Interventional Phase II clinical trial protocol NCT04609566 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-26 Enrollment: 161 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04609566
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)161 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04609566
Protocol FieldVerified Registry Value
NCT IdentifierNCT04609566
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment161 participants (ACTUAL)
Registered Start Date2021-01-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04609566
Hospital Research SiteLocationSite Profile
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI